Table 2

Summary of change from baseline to week 24 in van der Heijde-Sharp score (randomised patients)

Placebo+MTXGolimumab 2 mg/kg+MTX
Randomised patients (n)197395
 Change in total vdH-S score
  Mean (SD)1.09±3.190.03±1.90
  Median (IQ range)0.00 (0.00, 1.49)0.00 (−0.50, 0.50)
   p Value vs placebo+MTX<0.001
 Patients with screening CRP ≥1.5 mg/dL (n)163326
  Mean (SD)1.10±3.21−0.03±1.78
  Median (IQ range)0.00 (0.00, 1.50)0.00 (−0.50, 0.50)
 Patients with screening CRP <1.5 mg/dL (n)3469
  Mean (SD)1.04±3.190.31±2.39
  Median (IQ range)0.00 (0.00, 0.50)0.00 (−0.50, 1.00)
 Total hand vdH-S score
  Mean (SD)0.66±2.110.01±1.56
  Median (IQ range)0.00 (0.00, 0.75)0.00 (−0.48, 0.50)
   p Value vs placebo+MTX<0.001
 Total feet vdH-S score
  Mean (SD)0.43±1.690.03±0.88
  Median (IQ range)0.00 (0.00, 0.00)0.00 (0.00, 0.00)
   p Value vs placebo+MTX0.012
Change in Erosion score
  Mean (SD)0.53±2.09−0.12±1.15
  Median (IQ range)0.00 (0.00, 0.50)0.00 (−0.50, 0.00)
   p Value vs placebo+MTX<0.001
Change in JSN score
  Mean (SD)0.56±1.730.14±1.33
  Median0.00 (0.00, 0.50)0.00 (0.00, 0.00)
   p Value vs placebo+MTX0.002
  • CRP, C reactive protein; JSN, joint space narrowing; MTX, methotrexate; vdH-S, van der Heijde-Sharp.